
    
      A double-blind, randomized, placebo, controlled trial with an open label extension for those
      subjects with end stage renal disease (ESRD).

      Patients with ESRD will be randomized to receive either FOSTRAP™ 20 mg BID, FOSTRAP™ 40 mg
      BID or matching placebo 2x/day. All subjects will participate in a 4 week chewing period
      followed by a 4 week follow up period. All subjects will then enter an open label 2 week
      extension phase in which they will receive FOSTRAP™ 20 mg TID.

      Patients with chronic kidney disease (CKD) not on dialysis will receive either FOSTRAP™ 20 mg
      3x/day or placebo TID for 4 weeks followed by a 4 week follow up period.
    
  